Wanbury Limited (WANBURY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Wanbury Limited (WANBURY) has a cash flow conversion efficiency ratio of -0.053x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs-56.53 Million ≈ $-611.33K USD) by net assets (Rs1.07 Billion ≈ $11.60 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Wanbury Limited - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Wanbury Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Wanbury Limited balance sheet liabilities for a breakdown of total debt and financial obligations.
Wanbury Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Wanbury Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bridgemarq Real Estate Services Inc
TO:BRE
|
-0.014x |
|
Prozone Realty Limited
NSE:PROZONER
|
0.044x |
|
CAIRO MEZZ PLC EO-10
F:6H3
|
N/A |
|
Adverum Biotechnologies Inc
NASDAQ:ADVM
|
0.505x |
|
Media Prima Bhd
KLSE:4502
|
0.055x |
|
Petrochemical
TA:PTCH
|
-0.001x |
|
BioPorto
CO:BIOPOR
|
-0.575x |
|
ALT5 Sigma Corporation
NASDAQ:ALTS
|
-0.006x |
Annual Cash Flow Conversion Efficiency for Wanbury Limited (2006–2025)
The table below shows the annual cash flow conversion efficiency of Wanbury Limited from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see WANBURY market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs592.72 Million ≈ $6.41 Million |
Rs261.02 Million ≈ $2.82 Million |
0.440x | +209.30% |
| 2024-03-31 | Rs279.41 Million ≈ $3.02 Million |
Rs39.78 Million ≈ $430.23K |
0.142x | +123.60% |
| 2023-03-31 | Rs-328.16 Million ≈ $-3.55 Million |
Rs197.97 Million ≈ $2.14 Million |
-0.603x | +65.13% |
| 2022-03-31 | Rs-234.20 Million ≈ $-2.53 Million |
Rs405.23 Million ≈ $4.38 Million |
-1.730x | -1520.63% |
| 2021-03-31 | Rs-1.56 Billion ≈ $-16.90 Million |
Rs166.81 Million ≈ $1.80 Million |
-0.107x | +65.30% |
| 2020-03-31 | Rs-1.43 Billion ≈ $-15.51 Million |
Rs441.33 Million ≈ $4.77 Million |
-0.308x | -116.56% |
| 2019-03-31 | Rs-2.09 Billion ≈ $-22.63 Million |
Rs297.31 Million ≈ $3.22 Million |
-0.142x | +18.93% |
| 2018-03-31 | Rs-1.85 Billion ≈ $-19.97 Million |
Rs323.65 Million ≈ $3.50 Million |
-0.175x | +38.09% |
| 2017-03-31 | Rs-1.53 Billion ≈ $-16.58 Million |
Rs433.86 Million ≈ $4.69 Million |
-0.283x | -7.32% |
| 2016-03-31 | Rs-1.63 Billion ≈ $-17.65 Million |
Rs430.53 Million ≈ $4.66 Million |
-0.264x | -16.35% |
| 2015-03-31 | Rs-1.77 Billion ≈ $-19.16 Million |
Rs401.67 Million ≈ $4.34 Million |
-0.227x | +17.67% |
| 2014-03-31 | Rs-1.65 Billion ≈ $-17.85 Million |
Rs454.48 Million ≈ $4.92 Million |
-0.275x | +92.09% |
| 2013-03-31 | Rs-212.95 Million ≈ $-2.30 Million |
Rs741.21 Million ≈ $8.02 Million |
-3.481x | -980.07% |
| 2012-03-31 | Rs711.13 Million ≈ $7.69 Million |
Rs281.25 Million ≈ $3.04 Million |
0.395x | +747.00% |
| 2011-03-31 | Rs1.05 Billion ≈ $11.35 Million |
Rs49.02 Million ≈ $530.13K |
0.047x | -78.40% |
| 2010-03-31 | Rs1.92 Billion ≈ $20.81 Million |
Rs416.05 Million ≈ $4.50 Million |
0.216x | -52.49% |
| 2009-03-31 | Rs1.58 Billion ≈ $17.13 Million |
Rs720.95 Million ≈ $7.80 Million |
0.455x | +318.55% |
| 2007-03-31 | Rs1.29 Billion ≈ $13.96 Million |
Rs-268.83 Million ≈ $-2.91 Million |
-0.208x | -346.01% |
| 2006-03-31 | Rs1.01 Billion ≈ $10.94 Million |
Rs-47.21 Million ≈ $-510.60K |
-0.047x | -- |
About Wanbury Limited
Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for anti-infectives, pain and analgesics, respiratory, gastroenterology, gynecology, rheumatology, and central nervous system, as well as for vitamins, minerals, and nutrition. It also provides API products for antidiabetics, antihistamines,… Read more